Journal article

Clinical utility of quantifying hepatitis B surface antigen in African patients with chronic hepatitis B

Gerrit Post, Jess Howell, Amina Sow, Gibril Ndow, Isabelle Chemin, Gora Lo, Amie Cessay, Damien Cohen, Ramou Njie, Souleymane Toure, Madoky Diop, Roger Sombie, Jean Nana, Vincent Leroy, Karine Lacombe, Lamin Bojang, Frank Tacke, Coumba Toure-Kane, Mourtalla Ka, Maimuna Mendy Show all



The clinical utility of quantifying hepatitis B surface antigen (qHBsAg) levels in African subjects with chronic hepatitis B virus (HBV) infection has been poorly documented. From a multicentre cohort of 944 HBV-infected African patients, we aimed to assess whether qHBsAg alone can accurately identify i) those in a HBeAg-negative chronic HBV infection phase at low risk of liver disease progression and ii) those in need of antiviral therapy according to the 2017 EASL guidelines. We analysed 770 HBV mono-infected treatment-naïve patients, mainly males (61%) from West Africa (92%), median age 35 years (IQR: 30-44), median HBV DNA: 95.6 IU/ml (10.0-1,300.0), median qHBsAg 5,498 IU/ml (1,171-13,0..

View full abstract